Nisin A
(Synonyms: 乳酸链球菌素,Ambicin N|Nisaplin®) 目录号 : GC10569
An antibiotic
Cas No.:1414-45-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
-
Specific Activity: 900IU/mg
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nisin A is an antibacterial peptide.
Nisin A is produced by the lactic acid bacterium L. lactis using uncommon amino acids, including lanthionine, and is a member of the class of antibiotics referred to as lantibiotics.
In vitro: Previous study showed that the sperm motility could be completely inhibited with nisin A. The minimum effective concentration of nisin A required to immobilize sperm in vitro within 20 s was found to be 50 microg in rat, 200 microg in rabbit and 300-400 microg in monkey and human. Such inhibitory effect on sperm motility was found to be dose- and time-dependent [1].
In vivo: Intravaginal administration of nisin A before mating during proestrus-estrous transition phase caused complete arrest of sperm motility and blockage of conception. Subacute toxicity studies in rats showed that, repetitive intravaginal application of nisin A at the dose of 200 microg for 14 days caused no abnormalities either in the length of estrous cycle or in the morphology of vaginal epithelial cells. Moreover, no histopathological abnormalities in vaginal tissue or any change in blood and serum biochemical profiles were seen. In addition, no adverse effects were found on subsequent reproductive performance, development of pups and neonate survival [1].
Clinical trial: Up to now, nisin A is still in the preclinical development stage.
Reference:
[1] Aranha C, Gupta S, Reddy KV. Contraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studies. Contraception. 2004 Apr;69(4):333-8.
| Cas No. | 1414-45-5 | SDF | |
| 别名 | 乳酸链球菌素,Ambicin N|Nisaplin® | ||
| 化学名 | L-isoleucyl-(Z)-2,3-didehydro-2-aminobutanoyl-D-cysteinyl-L- isoleucyl-2,3-didehydroalanyl-L-leucyl-L-cysteinyl-threo-3- mercapto-D-2-aminobutanoyl-L-prolylglycyl-L-cysteinyl-L-lysyl- threo-3-mercapto-D-2-aminobutanoylglycyl-L-alanyl-L-leucyl-L- methionyl | ||
| Canonical SMILES | O=C(N1[C@@]([H])(CCC1)C(NC2)=O)[C@@H](NC([C@@H](NC([C@H](CC(C)C)NC(C(N3)=C)=O)=O)CSC[C@@H](NC(/C(NC([C@H]([C@H](CC)C)N)=O)=C/C)=O)C(N[C@]([H])(C3=O)[C@H](CC)C)=O)=O)[C@H](C)SC[C@@H](C(N[C@H](C(N[C@@H]([C@H](C)SC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C | ||
| 分子式 | C143H230N42O37S7 | 分子量 | 3354.1 |
| 溶解度 | ≤0.25mg/ml in DMSO | 储存条件 | -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2981 mL | 1.4907 mL | 2.9814 mL |
| 5 mM | 0.0596 mL | 0.2981 mL | 0.5963 mL |
| 10 mM | 0.0298 mL | 0.1491 mL | 0.2981 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。